Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris

Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant
metabolites after topical dermal application of IDP-121 lotion in subjects with moderate to
severe acne vulgaris under maximal use conditions.

Key Inclusion Criteria:

- Male or female, between the ages of 9 and <17 years (16 years 11 months inclusive).

- Written and oral informed consent must be obtained. Subjects less than age of consent
must sign an assent for the study and a parent or legal guardian must sign the
informed consent.

- Subject must have a score of 3 (moderate) to 4 (severe) on the Evaluator's Global
Severity Assessment at the screening and baseline visit in the facial area.

- Subjects with facial acne inflammatory lesions count no less than 20 but no more than
40.

- Subjects with facial acne non-inflammatory lesions count no less than 20 but no more
than 100.

Key Exclusion Criteria:

- Use of investigational drug or device within 30 days of enrollment or participation in
research study or concurrent study with this study.

- Any dermatological conditions on the face that could interfere with clinical
evaluations acne conglobate, acne fulminans, secondary acne, perioral dermatitis,
clinical significant rosacea, gram negative folliculitis.

- Any underlying disease(s) or some other dermatological condition of the face that
requires the use of interfering topical or systemic therapy or makes evaluations and
lesion count inconclusive.

- Subjects with facial beard or mustache that could interfere with any study
assessments.